1. Home
  2. AEAQ vs TENX Comparison

AEAQ vs TENX Comparison

Compare AEAQ & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEAQ

Activate Energy Acquisition Corp. Class A Ordinary Share

N/A

Current Price

$10.01

Market Cap

312.2M

Sector

N/A

ML Signal

N/A

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$14.53

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEAQ
TENX
Founded
2025
1967
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
312.2M
317.8M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
AEAQ
TENX
Price
$10.01
$14.53
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
26.9K
1.4M
Earning Date
01-01-0001
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.87
$5.80
52 Week High
$10.09
$19.40

Technical Indicators

Market Signals
Indicator
AEAQ
TENX
Relative Strength Index (RSI) 60.48 46.84
Support Level $9.88 $12.84
Resistance Level $10.09 $16.35
Average True Range (ATR) 0.00 1.21
MACD -0.00 -0.33
Stochastic Oscillator 80.00 4.81

Price Performance

Historical Comparison
AEAQ
TENX

About AEAQ Activate Energy Acquisition Corp. Class A Ordinary Share

Activate Energy Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: